OM
DTIL icon

Opaleye Management’s Precision BioSciences DTIL Stock Holding History

Opaleye Management’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,463
Closed -$1.89M – 41
2021
Q3 		$1.89M Buy
+5,463
New +$1.85M 0.35% 41

Other funds holding DTIL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Opaleye Management's DTIL Position: Q4 2021 in Review

Opaleye Management sold out of Precision BioSciences (DTIL) in Q4 2021, closing a stake of 5,463 shares — an estimated $1.89M sold.

Opaleye Management first reported a position in DTIL in Q3 2021 and held it in 1 quarter. The position peaked at $1.89M in Q3 2021. 134 funds tracked by Wall St. Rank hold DTIL as of Q4 2021.

  • Opaleye Management reported no remaining Precision BioSciences position as of Q4 2021 after selling out during the quarter.
  • Opaleye Management sold 5,463 Precision BioSciences shares in Q4 2021, an estimated $1.89M.
  • Opaleye Management first reported a position in Precision BioSciences in Q3 2021 and held it in 1 quarter.
  • Opaleye Management's Precision BioSciences position peaked at $1.89M in Q3 2021.
  • 134 funds tracked by Wall St. Rank held Precision BioSciences as of Q4 2021.

Based on Opaleye Management's 13F filing for Q4 2021, filed 14 Feb 2022.